Page last updated: 2024-08-18

pyrazolanthrone and Movement Disorders

pyrazolanthrone has been researched along with Movement Disorders in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Li, H; Wang, Y; Wei, Z; Zhang, Y; Zhang, Z; Zhou, H	1

Other Studies

1 other study(ies) available for pyrazolanthrone and Movement Disorders

Article	Year
JNK inhibitor protects dopaminergic neurons by reducing COX-2 expression in the MPTP mouse model of subacute Parkinson's disease. Journal of the neurological sciences, 2009, Oct-15, Volume: 285, Issue:1-2 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anthracenes; Cell Death; Cyclooxygenase 2; Disease Models, Animal; Dopamine; Enzyme Inhibitors; JNK Mitogen-Activated Protein Kinases; Male; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Movement Disorders; Neurons; Parkinson Disease; Parkinsonian Disorders; Phosphorylation; Proto-Oncogene Proteins c-jun; Random Allocation; Substantia Nigra	2009

Article

Year

JNK inhibitor protects dopaminergic neurons by reducing COX-2 expression in the MPTP mouse model of subacute Parkinson's disease.

Journal of the neurological sciences, 2009, Oct-15, Volume: 285, Issue:1-2

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anthracenes; Cell Death; Cyclooxygenase 2; Disease Models, Animal; Dopamine; Enzyme Inhibitors; JNK Mitogen-Activated Protein Kinases; Male; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Movement Disorders; Neurons; Parkinson Disease; Parkinsonian Disorders; Phosphorylation; Proto-Oncogene Proteins c-jun; Random Allocation; Substantia Nigra

2009